Life Sciences

The need for alignment to achieve health outcomes for all

As populations age and chronic diseases become commonplace, health care will take an ever larger share of GDP. Scientific progress, augmented intelligence and a more empowered patient are driving changes in the delivery of health care to a personalized experience that demands health outcomes as the core metric. This is causing a power shift among traditional stakeholder groups, with new entrants (often not driven by profit) disrupting incumbents.

Innovation, productivity and access to patients remain the industry’s biggest challenges. These trends challenge the capital strategy of every link in the life sciences value chain, from R&D and product supply to product launch and patient-centric operating models.

Our Global Life Sciences Sector brings together a worldwide network of 11,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage. We can help you navigate your way forward and achieve sustainable success in the new health-outcomes-driven ecosystem.

EY's top five Knowledge Development Box (KDB) considerations for Life Science companies

The KDB is aimed at incentivising innovative R&D activities by taxing qualifying profits from patented inventions and copyrighted software at 6.25%. This following infographic showcases the 5 key areas Life Sciences companies should consider in accessing the benefits of KDB.  

For more details, read EY’s KDB for Life Sciences report.

EY's top five Knowledge Development Box (KDB) considerations for Life Science companies

    Contact us

    EY - Aidan Meagher

    Aidan Meagher
    Head of Life Sciences
    Tax Services
     +353 (1) 221 1139
    linkedIn Aidan Meagher Aidan Meagher


    EY - Graham Reid

    Graham Reid
    Corporate Finance
    Head of Transaction Advisory Services
     +353 1 221 1449
    linkedIn Graham Reid Graham Reid


    EY - Feargal De Freine

    Feargal De Freine
    Assurance Partner
     +353 1 221 1636
    linkedIn Feargal De Freine Feargal De Freine


    Connect with us

    Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.


    Vital Signs

    EY - The MedTech Strategist Innovation Summit - Dublin 2017

    EY are proud platinum sponsors of the Innovation in MedTech Summit, Dublin, 25 – 27 April 2017, The Shelbourne Hotel, Dublin. This annual conference is the leading MedTech investment forum in Europe.

    EY - Optimise for today? Build for tomorrow?

    Optimise for today? Build for tomorrow?

    Whether you’re transforming your business today, or transform the sector tomorrow. EY can help you do both better. Download our brochure.

    EY - Ireland Life Sciences

    Ireland Life Sciences

    EY discusses the Life Sciences sector

    EY - Leanne Storan discusses the KDB

    EY's Leanne Storan discusses the KDB and the benefits for Life Sciences companies in Ireland

    EY - Download report

    Download EY's report on the Top five KDB considerations for Life Sciences companies